MEIP Stock Analysis
ME
Uncovered
MEI Pharma Inc is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
High score
MEI Pharma, Inc. is a pharmaceutical company, which engages in the development of pharmaceutical compounds. The company is headquartered in San Diego, California and currently employs 102 full-time employees. The company went IPO on 2003-12-18. The firm is engaged in the development and commercialization of novel cancer therapies. The firm's portfolio of drug candidates includes three clinical-stage assets: Zandelisib, Voruciclib, and ME-344. Zandelisib is an oral phosphatidylinositol 3-kinase delta (PI3K) in clinical development for the treatment of B-cell malignancies. Zandelisib is in multiple ongoing clinical studies intended to support marketing applications with the United States Food and Drug Administration (FDA) and other regulatory authorities globally. Voruciclib is an oral cyclin-dependent kinase 9 (CDK9) inhibitor, which is used in therapies for the treatment of hematologic malignances and solid tumors. ME-344 is a Mitochondrial Inhibitor used for the treatment of solid tumors.